Serial #79406335 Trademark

Medical and pharmaceutical research services; scientific research for medical purposes in the field/for the treatment of respiratory disorders, chronic obstructive pulmonary disease (COPD), acute exacerbations of chronic obstructive pulmonary disease (AECOPD), bronchodilators and anti-asthma preparations, osteogenesis imperfecta (OI) (brittle bone syndrome), bone density, bone weakness, bone-related diseases, bone disorders associated with low bone formation, low bone mineral density, low bone mineral content, low bone mass, or low bone strength, diseases or disorders associated with collagen mutations, obesity, testosterone levels, aromatase inhibitors (AIs), hypogonadotrophic hypogonadism (HH), antibiotics, diseases mediated by antitrypsin deficiency (AATD), respiratory diseases, inflammatory diseases and conditions, SARS-COV infections, COVID-19, fibrosis, graft rejection, graft versus host disease (GVHD), bronchiolitis obliterans syndrome (BOS), cancer, checkpoint inhibitor naïve cancer, cervical cancer, breast cancer, ovarian cancer, clear cell ovarian cancer, sarcoma, soft tissue sarcoma, de-differentiated liposarcoma sarcoma, germ cell tumours, testicular germ cell tumours, uveal melanomas, cancers with a high tumour mutational burden (TMB), microsatellite stable cancer, endometrial cancer, PVR positive cancer, TIGIT positive cancer, PD-L1 negative cancer, CD226 positive cancer, CD8 positive cancer, cancer involving reducing Tregs and promoting myeloid cell activation; medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information, advisory and consultancy services relating to all the aforesaid services.

Pharmaceutical preparations and drugs for the treatment of respiratory disorders; pharmaceutical preparations and drugs for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical preparations and drugs for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); pharmaceutical preparations and drugs namely bronchodilators and anti-asthma preparations; pharmaceutical preparations and drugs for the treatment of osteogenesis imperfecta (OI) (brittle bone syndrome); pharmaceutical preparations and drugs to improve bone density and treat bone weakness; pharmaceutical preparations and drugs for the treatment of bone-related diseases; pharmaceutical preparations and drugs for the treatment of bone disorders associated with low bone formation, low bone mineral density, low bone mineral content, low bone mass, or low bone strength; pharmaceutical preparations and drugs for the treatment of diseases or disorders associated with collagen mutations; pharmaceutical preparations and drugs for the treatment of obesity; pharmaceutical preparations and drugs for treating testosterone levels; pharmaceutical preparations and drugs namely aromatase inhibitors (AIs); pharmaceutical preparations and drugs for treating hypogonadotrophic hypogonadism (HH); antibiotics; pharmaceutical preparations and drugs for the treatment of diseases mediated by antitrypsin deficiency (AATD); pharmaceutical preparations and drugs for the treatment of respiratory diseases; pharmaceutical preparations and drugs for the treatment or prophylaxis of inflammatory diseases and conditions; pharmaceutical preparations and drugs for the treatment or prevention of a symptom or complication attributable of a SARS-COV infection; pharmaceutical preparations and drugs for the treatment of COVID-19; pharmaceutical preparations and drugs for the treatment or prevention of fibrosis; pharmaceutical preparations and drugs for the treatment or prevention of graft rejection; pharmaceutical preparations and drugs for the treatment or prevention of graft versus host disease (GVHD); pharmaceutical preparations and drugs for the treatment or prevention of bronchiolitis obliterans syndrome (BOS); pharmaceutical preparations and drugs for the treatment of cancer; pharmaceutical preparations and drugs for the treatment of checkpoint inhibitor naïve cancer; pharmaceutical preparations and drugs for the treatment of cervical cancer; pharmaceutical preparations and drugs for the treatment of breast cancer; pharmaceutical preparations and drugs for the treatment of ovarian cancer; pharmaceutical preparations and drugs for the treatment of clear cell ovarian cancer; pharmaceutical preparations and drugs for the treatment of sarcoma; pharmaceutical preparations and drugs for the treatment of soft tissue sarcoma; pharmaceutical preparations and drugs for the treatment of de-differentiated liposarcoma sarcoma; pharmaceutical preparations and drugs for the treatment of germ cell tumours; pharmaceutical preparations and drugs for the treatment of testicular germ cell tumours; pharmaceutical preparations and drugs for the treatment of uveal melanomas; pharmaceutical preparations and drugs for the treatment of cancers with a high tumour mutational burden (TMB); pharmaceutical preparations and drugs for the treatment of microsatellite stable cancer; pharmaceutical preparations and drugs for the treatment of endometrial cancer; pharmaceutical preparations and drugs for the treatment of PVR positive cancer; pharmaceutical preparations and drugs for the treatment of TIGIT positive cancer; pharmaceutical preparations and drugs for the treatment of PD-L1 negative cancer; pharmaceutical preparations and drugs for the treatment of CD226 positive cancer; pharmaceutical preparations and drugs for the treatment of CD8 positive cancer; pharmaceutical preparations and drugs for the treatment of cancer involving reducing Tregs and promoting myeloid cell activation.